Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: sildenafil citrate

« Back to Dashboard
Sildenafil citrate is the generic ingredient in three branded drugs marketed by Pfizer, Aurobindo Pharma Ltd, Actavis Grp Ptc, Amneal Pharms, Apotex Corp, Dr Reddys Labs Ltd, Hetero Labs Ltd V, Macleods Pharms Ltd, Mylan Pharms Inc, Teva Pharms, Torrent Pharms Ltd, Watson Labs Inc, and Pfizer Ireland, and is included in sixteen NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for sildenafil citrate. Twelve suppliers are listed for this compound. There are eleven tentative approvals for this compound.

Summary for Generic Name: sildenafil citrate

Tradenames:3
Patents:1
Applicants:13
NDAs:16
Drug Master File Entries: see list20
Suppliers / Packaging: see list75
Therapeutic Class:Respiratory Tract Agents

Pharmacology for Ingredient: sildenafil citrate

Tentative approvals for SILDENAFIL CITRATE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL25MG
<disabled><disabled>TABLET; ORAL50MG
<disabled><disabled>TABLET; ORAL100MG

Clinical Trials for: sildenafil citrate

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Status: Completed Condition: Pulmonary Arterial Hypertention

Sildenafil for Prevention of Cerebral Vasospasm
Status: Withdrawn Condition: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
Status: Not yet recruiting Condition: Erectile Dysfunction

Viagra in the Treatment of Primary Dysmenorrhea
Status: Completed Condition: Dysmenorrhea

Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Status: Recruiting Condition: Solid Tumor

Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Status: Completed Condition: Pulmonary Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
REVATIO
sildenafil citrate
TABLET;ORAL021845-001Jun 3, 2005RXYes<disabled><disabled>
Aurobindo Pharma Ltd
SILDENAFIL CITRATE
sildenafil citrate
TABLET;ORAL203963-001Nov 18, 2015RXNo<disabled><disabled>
Actavis Grp Ptc
SILDENAFIL CITRATE
sildenafil citrate
TABLET;ORAL200149-001Feb 25, 2013RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: sildenafil citrate

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
REVATIO
sildenafil citrate
SOLUTION;INTRAVENOUS022473-001Nov 18, 20095,250,534*PED<disabled>
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 19985,250,534*PED<disabled>
Pfizer
REVATIO
sildenafil citrate
TABLET;ORAL021845-001Jun 3, 20055,250,534*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc